Management of Interstitial Pneumonitis with Autoimmune Features

Initial Treatment Approach

The American College of Rheumatology recommends initial treatment with corticosteroids and early introduction of steroid-sparing agents like mycophenolate or rituximab to minimize steroid-related complications 1, 2
Begin with methylprednisolone 1 mg/kg/day for symptomatic pneumonitis, and for severe cases, initiate higher doses of methylprednisolone (2 mg/kg/day) 3, 5
After initial control, taper prednisone gradually over >1 month for moderate cases and >2 months for severe cases 3, 2

Monitor blood glucose regularly and treat hyperglycemia according to standard guidelines, and for steroid-induced diabetes with ketoacidosis, hold immunotherapy and hospitalize for standard treatment 3
Provide calcium and vitamin D supplementation with prolonged steroid use, and consider bone density testing and prophylactic bisphosphonates for patients on long-term steroids 3, 4, 2
Prescribe proton pump inhibitor therapy for GI prophylaxis in all patients receiving steroids for pneumonitis 3, 4
Consider prophylactic antibiotics for pneumocystis pneumonia (PCP) for patients receiving ≥20 mg methylprednisolone or equivalent for ≥4 weeks 3, 4

For rapidly progressive interstitial lung disease, consider pulse intravenous methylprednisolone as first-line treatment, and for patients with concurrent autoimmune features, tailor immunosuppressive therapy based on the specific autoimmune profile 1
In elderly patients (>70 years) or those with comorbidities, carefully weigh benefits against risks of aggressive immunosuppression 6, 2

Avoid long-term corticosteroid monotherapy, as it causes substantial morbidity without proven benefit, and don't continue therapy indefinitely without objective evidence of improvement or stabilization 2, 6
Don't delay introduction of steroid-sparing agents in patients requiring prolonged treatment, and avoid using high-dose corticosteroids without ruling out infection, especially in immunocompromised patients 1, 4